High degrees of this molecule are connected with an increased threat of cardiovascular disease. It’s been suggested that providing B-vitamin supplements could help regulate degrees of homocysteine, reducing the risk of cardiovascular disease and death thereby. But based on the researchers, there is no scientific basis for this claim. The review included eight trials including a total of 24,210 people. None of the eight trials individually supported the essential proven fact that giving B-vitamin products could prevent coronary disease. Together the data show that B-vitamin products, whether compared with placebos or standard care, have no effect on the incidence of heart attack, death or stroke connected with heart disease. Prescription of these supplements can’t be justified, unless fresh evidence from large top quality trials alters our conclusions.Dr. Austin also shown this work at a recent international conference in Japan where he was the just Canadian researcher to end up being invited to speak.
Bayer’s radium-223 chloride Stage III trial in CRPC, bone metastases meet principal endpoint Bayer Health care Pharmaceuticals Inc. Today announced that the Stage III ALSYMPCA trial evaluating Bayer’s investigational substance, radium-223 chloride, which is certainly exclusively certified from Algeta ASA, in individuals with castration-resistant prostate malignancy and bone metastases fulfilled its main endpoint by considerably improving overall survival.0022, HR = 0.699, the median overall survival was 14.0 months for radium-223 chloride and 11.2 months for placebo).